BioXcel Therapeutics (BTAI) Short-Term Debt repayments (2017 - 2018)
BioXcel Therapeutics (BTAI) recorded quarterly Short-Term Debt repayments of -$371000.0 in Q1 2018, down 18650.0% quarter-over-quarter from $2000.0 in Q4 2017.
BioXcel Therapeutics (BTAI) Short-Term Debt repayments (2017 - 2018) Analysis & Trends
BioXcel Therapeutics' Short-Term Debt repayments history runs 2 years deep, the most recent figure standing at -$371000.0 for Q1 2018.
- In Q1 2018, Short-Term Debt repayments changed N/A year-over-year to -$371000.0; the TTM figure through Dec 2018 stood at -$371000.0 (changed N/A YoY), while the FY2018 annual figure was -$371000.0, down 200.0% from the prior year.
- Short-Term Debt repayments was -$371000.0 for Q1 2018 at BioXcel Therapeutics, down from $2000.0 in the prior quarter.
- In the past five years, Short-Term Debt repayments ranged from a high of $84000.0 in Q3 2017 to a low of -$371000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn | - |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | - |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn | - |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn | - |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn | - |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn | - |
| 10 | BioXcel Therapeutics | 27.11 Mn | 27.11 Mn | -77,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | -371,000.00 |
| Mar 31, 2018 | -371,000.00 |
| Dec 31, 2017 | 2,000.00 |
| Dec 31, 2017 | 2,000.00 |
| Sep 30, 2017 | 84,000.00 |
| Sep 30, 2017 | 84,000.00 |